Patent Granted in Japan

BiVictriX Therapeutics PLC

15 November 2023

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

Patent Granted in Japan Providing Further Broad Protection for BVX001

·    Provides broad protection for lead product, BVX001, in a market where AML is the most common acute leukaemia, accounting for c.70% of all myeloid leukaemias

·    Builds upon the recent US patent grant, providing strong IP position in two key global markets

·    Prosecution for the patent family currently being pursued in a further six global jurisdictions

Alderley Park, 15 November 2023 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a differentiated approach to develop novel, next-generation anti-cancer precision Antibody Drug Conjugates, offering substantially improved cancer cell selectivity and therapeutic activity, announces today that the Japanese Patent Office ("JPO") has granted a patent providing broad protection for the Company's lead asset, BVX001.

This follows the Company's announcement on 23 August 2023 regarding the grant by the United  States Patent and Trademark Office. This latest patent grant from the JPO is part of the Company's strategy of broad protection for BVX001. The claims granted within this patent (patent number 7337824), which belongs to the wider patent family "Therapy", are currently being prosecuted in a further six jurisdictions worldwide to provide ultimate broad protection for BVX001 at the highest antigen level.  

Tiffany Thorn, CEO of BiVictriX commented: "The approval of this patent in Japan, which follows swiftly after the granting of our patent in the US, puts BiVictriX in a strong IP position in two key global markets.  With plans to prosecute in a further six global jurisdictions, we are building strong protection for our lead therapeutic asset, at the broadest level, enhancing the value of BVX001 as we prepare for first in human studies and refine the optimal drug development and commercialisation strategy."

ENDS For more information, please contact: BiVictriX Therapeutics plc Tiffany Thorn, Chief Executive Officer Michael Kauffman, Non-Executive Chairman Email: [e-mail] SP Angel Corporate Finance LLP (NOMAD and Broker)   Tel: [phone] David Hignell, Kasia Brzozowska (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking) Panmure Gordon (UK) Limited (Joint Broker)   Tel: [phone] Rupert Dearden/Freddy Crossley/Emma Earl ICR Consilium Mary-Jane Elliott, Namrata Taak, Max Bennett, Emmalee Hoppe Tel: [phone] Email: [e-mail]

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or "Bi-Cygni® fingerprints", on tumour cells, which are largely absent from healthy cells.

BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company's novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com  

 

END